Arcturus Therapeutics Holdings Inc.
$270.74M- Market cap
- $449.65M
- Debt
- +$52.00M
- Cash
- −$230.91M
Capital structure 90% equity / 10% debt · EV / Revenue 3.30x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ARCT stock price at premium vs GTX $15.82 current versus $4.22 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GTX's multiple
Implied fair value · at ARCT's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ARCT FY 2025 (ended Dec 31, 2025) · GTX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 3.30x
Capital structure 79% equity / 21% debt · EV / Revenue 1.81x · EV / EBITDA 11.05x
GTX carries the larger enterprise value at $6.48B against $270.74M; GTX trades on the lower EV / Revenue multiple (1.81x vs 3.30x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Garrett Motion Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
-1.77x
Net debt / EBITDA
Leverage against operating earnings
2.72x
2.12x
Cash and equivalents
Liquid reserves on the balance sheet
$230.91M
$177.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ARCT vs MRNA
BioNTech SE
ARCT vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
ARCT vs ALNY
Sarepta Therapeutics, Inc.
ARCT vs SRPT
Intellia Therapeutics, Inc.
ARCT vs NTLA
BORGWARNER INC
ARCT vs BWA
AUTOLIV INC
ARCT vs ALV
DANA INC
ARCT vs DAN
MODINE MANUFACTURING CO
ARCT vs MOD
AMERICAN AXLE & MANUFACTURING HOLDINGS INC
ARCT vs AXL
LEAR CORP
ARCT vs LEA
$52.00M
$1.42B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.